Two editors at The Verge discuss investment into 'disruptive' healthcare companies.
Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.
The firm can now market its complete slate of diagnostic tests in New York. It also offers array-based tests for pregnancy loss and prenatal diagnosis.
Both tests analyze tumor and normal samples by next-generation sequencing to help doctors make therapy decisions for cancer patients.
FDA has approved BMS' Opdivo with a test to guide treatment strategies, but according to the drug label testing isn't required to identify who should receive the drug.
Scientists from The Francis Crick Institute have applied to UK regulators to use CRISPR/Cas9 genome editing in an upcoming study of miscarriage.
Forbes' Matthew Herper reports that the US Food and Drug Administration is approving more drugs than not.
The CombiSNP Array for Prenatal Diagnosis detects chromosomal imbalances not detected by karyotyping from chorionic villi and amniocentesis samples.
Sigma-Aldrich still must meet certain requirements to sell parts of its solvents and inorganics business in Europe to complete the acquisition.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.